Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Mullard

Showing results (81-90 of 684) with videos related to

Pageof 69
Sort By:
Nature Reviews. Drug Discovery|June 30, 2017
Chinese biopharma starts feeding the global pipelineAsher Mullard
Nature Reviews. Drug Discovery|June 5, 2019
Achaogen bankruptcy highlights antibacterial development woesAsher Mullard
Nature Reviews. Drug Discovery|August 31, 2018
FDA approves second GPCR-targeted antibodyAsher Mullard
Nature Reviews. Drug Discovery|June 5, 2019
NLRP3 inhibitors stoke anti-inflammatory ambitionsAsher Mullard
Nature Reviews. Drug Discovery|October 2, 2018
Chi-Med scores key approval for 'discovered in China' cancer drugAsher Mullard
Nature Reviews. Drug Discovery|October 2, 2018
Painkilling anti-NGF antibodies stage phase III comebackAsher Mullard
Nature Reviews. Drug Discovery|March 12, 2022
FDA approves second BCMA-targeted CAR-T cell therapyAsher Mullard
Nature Reviews. Drug Discovery|March 12, 2022
R&D budgets boom, but success rates falterAsher Mullard
Nature Reviews. Drug Discovery|March 16, 2022
Reflections on 10 years of the FDA's breakthrough therapy designationAsher Mullard
Nature Reviews. Drug Discovery|October 2, 2019
PCSK9-lowering RNAi contender clears first phase III trialAsher Mullard
Pageof 69

Showing results (81-90 of 684) with videos related to

Sort By:
Pageof 69
Nature Reviews. Drug Discovery|June 30, 2017
Chinese biopharma starts feeding the global pipelineAsher Mullard
Nature Reviews. Drug Discovery|June 5, 2019
Achaogen bankruptcy highlights antibacterial development woesAsher Mullard
Nature Reviews. Drug Discovery|August 31, 2018
FDA approves second GPCR-targeted antibodyAsher Mullard
Nature Reviews. Drug Discovery|June 5, 2019
NLRP3 inhibitors stoke anti-inflammatory ambitionsAsher Mullard
Nature Reviews. Drug Discovery|October 2, 2018
Chi-Med scores key approval for 'discovered in China' cancer drugAsher Mullard
Nature Reviews. Drug Discovery|October 2, 2018
Painkilling anti-NGF antibodies stage phase III comebackAsher Mullard
Nature Reviews. Drug Discovery|March 12, 2022
FDA approves second BCMA-targeted CAR-T cell therapyAsher Mullard
Nature Reviews. Drug Discovery|March 12, 2022
R&D budgets boom, but success rates falterAsher Mullard
Nature Reviews. Drug Discovery|March 16, 2022
Reflections on 10 years of the FDA's breakthrough therapy designationAsher Mullard
Nature Reviews. Drug Discovery|October 2, 2019
PCSK9-lowering RNAi contender clears first phase III trialAsher Mullard
Pageof 69